In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two pharmaceutical companies, CRA consultants were retained to assist in expert reports regarding industry practices regarding exclusivity of drug product candidates. A key issue was whether exclusivity was limited to individual antibodies and who had the right to select the antibodies for development. The reports addressed the scope and breadth of exclusivity in the industry and whether the payments in the contract were consistent with broad or narrow exclusivity.
Engagements
AAA dispute involving the scope and breadth of exclusivity of a development deal for monoclonal antibodies
Key contacts
Upcoming events
Asembia’s AXS26 Summit
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
GAR Live: Life Sciences
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...